Free Trial

Jupiter Asset Management Ltd. Raises Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Elanco Animal Health logo with Medical background

Key Points

  • Jupiter Asset Management Ltd. increased its stake in Elanco Animal Health by 19.1%, acquiring an additional 262,315 shares during the first quarter, bringing its total holdings to 1,636,779 shares valued at approximately $17.2 million.
  • Several institutional investors, including FMR LLC and Adage Capital Partners GP L.L.C., have significantly boosted their stakes in Elanco Animal Health, indicating strong investor interest in the company.
  • Analysts are optimistic about Elanco Animal Health, with multiple upgrades in ratings and target prices; UBS Group and Leerink Partners have set target prices of $18.00, reflecting bullish sentiment on the stock.
  • Looking to Export and Analyze Elanco Animal Health Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Jupiter Asset Management Ltd. grew its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 19.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,636,779 shares of the company's stock after acquiring an additional 262,315 shares during the quarter. Jupiter Asset Management Ltd. owned about 0.33% of Elanco Animal Health worth $17,186,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ELAN. American Century Companies Inc. increased its holdings in Elanco Animal Health by 1.8% in the 4th quarter. American Century Companies Inc. now owns 128,264 shares of the company's stock worth $1,553,000 after buying an additional 2,280 shares in the last quarter. LPL Financial LLC grew its stake in shares of Elanco Animal Health by 15.9% during the 4th quarter. LPL Financial LLC now owns 161,183 shares of the company's stock valued at $1,952,000 after purchasing an additional 22,163 shares during the period. Norges Bank bought a new stake in shares of Elanco Animal Health during the 4th quarter valued at about $47,424,000. Orion Portfolio Solutions LLC grew its stake in shares of Elanco Animal Health by 14.3% during the 4th quarter. Orion Portfolio Solutions LLC now owns 33,396 shares of the company's stock valued at $404,000 after purchasing an additional 4,169 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Elanco Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company's stock valued at $99,102,000 after purchasing an additional 312,165 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Stifel Nicolaus increased their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Finally, Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of "Moderate Buy" and a consensus price target of $16.17.

Get Our Latest Analysis on Elanco Animal Health

Elanco Animal Health Price Performance

NYSE ELAN traded up $2.26 during trading hours on Thursday, reaching $16.21. The company's stock had a trading volume of 2,730,263 shares, compared to its average volume of 5,320,148. The firm's 50-day moving average price is $14.20 and its 200-day moving average price is $12.02. The company has a quick ratio of 1.46, a current ratio of 2.71 and a debt-to-equity ratio of 0.68. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $16.70. The company has a market capitalization of $8.05 billion, a price-to-earnings ratio of 21.79, a PEG ratio of 2.76 and a beta of 1.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. During the same period in the previous year, the firm posted $0.30 EPS. The company's revenue was up 4.8% compared to the same quarter last year. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See Also

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Should You Invest $1,000 in Elanco Animal Health Right Now?

Before you consider Elanco Animal Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.

While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without
Palantir & AMD Earnings: Massive Options Setups Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines